https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

API-CAT Findings Support Existing NCCN Cancer-Associated VTE Guidance

API-CAT Findings Support Existing NCCN Cancer-Associated VTE Guidance

Reduced-dose apixaban maintains efficacy with less bleeding for extended CAT prophylaxis, reinforcing NCCN’s pre-existing guidance in intermediate to high-risk cancer patients.

administrator

Related Articles